EXPLORING DUAL BENEFITS: A REVIEW OF METHODS FOR SIMULTANEOUS ANALYSIS OF ANTIDIABETIC AND HYPOLIPIDAEMIC DRUGS

C. Mirfa Sherin*, K. Ayswarya, Cr. Biju, G. Jyothisree and Alina Mathew

ABSTRACT

Diabetes mellitus and dyslipidaemia pose a dual challenge in healthcare due to their intertwined pathophysiological mechanisms and cardiovascular implications. This review explores the complex interplay between these metabolic disorders and emphasizes the need for integrated management strategies. Traditional therapies involve antidiabetic and hypolipidaemic drugs, but emerging dual-action medications show promise in addressing both pathways simultaneously, leading to improved patient outcomes. Advanced analytical techniques such as chromatography, spectroscopy, and mass spectrometry play a crucial role in understanding the pharmacological profiles of these dual-action drugs. Challenges related to method specificity, sensitivity, and sample matrix complexity are discussed, along with future directions focusing on pharmacogenomics integration, multiplex assays, microfluidic devices, and quality control measures. The review underscores the importance of a comprehensive approach, blending scientific innovation, clinical expertise, and personalized treatment strategies to optimize therapeutic outcomes and mitigate cardiovascular risks in patients with diabetes mellitus and dyslipidaemia.

Keywords: Diabetes mellitus, Dyslipidaemia, Dual-action drugs, Simultaneous analysis, Integrated management.